BETA BLOCKER EVALUATION OF SURVIVAL TRIAL

充血性心力衰竭是影响美国数百万患者的主要公共健康问题。由于心脏移植只能提供给这些患者中的一小部分，药物治疗仍然是主流。目前的药物治疗改善了患者的存活率，但严重充血性心力衰竭患者的死亡率很高。如果β-受体阻滞剂将死亡率降低25%或更多，这一发现将对患有这种常见疾病的患者的护理产生重大影响。该项目旨在评估β-受体阻滞剂在改善高死亡率的常见临床疾病--III-IV级充血性心力衰竭患者存活率方面的有效性。布辛多洛是一种研究中的非选择性β受体阻滞剂，具有温和的血管扩张剂特性。它已经用于数百名心力衰竭患者，并获得了极好的耐受性。患者在布金多洛尔和普罗西博之间随机选择，向上滴定至最大耐受量，并跟踪观察4.5年。

Congestive heart failure is a major public health problem affecting millions of patients in the United States. Because heart transplantation can only be offered to a minority of these patients, pharmacological therapy remains the mainstay. Survival has improved with the use of current pharmacological therapy, but nevertheless mortality is high in patients with severe congestive heart failure. If beta-blockers reduce mortality by 25% or more, this finding would have major implications in the care of the patients with this common condition. This project seeks to evaluate the efficacy of beta-blockers to improve the survival of a common clinical condition with a high mortality rate, Class III-IV congestive heart failure. Bucindolol is an investigational non-selective beta-blocker with mild vasodilator properties. It has already been used in several hundred patients with heart failure and has been extremely well tolerated. Patients are randomized between Bucindolol and plcebo, titrated upward to the maximal tolerated dose of Bucindolol and followed for 4.5 years.